Remegen's Telitacicept met its primary endpoints in a Chinese trial, while a US-based Phase III trial in Sjögren's syndrome ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's ...